Narcotics and non narcotics analgesics
narcotics and non narcotics analgesics
Published on: Mar 3, 2016
Transcripts - Narcotics and non narcotics analgesics
Narcotics and Non-
An analgesic, or painkiller, is any member of the group
of drugs used to achieve analgesia — relief from pain.
Major classes of Analgesic Drugs include:
Narcotic analgesics are drugs that relieve pain,
by binding to opioid receptors, which are
present in the central and peripheral nervous
system, can cause numbness and induce a state
Natural Compounds: Morphine, Codeine, Papaverine
Semi-Synthetic: Diacetylmorphine (Heroin), benzylmorphine
Synthetic Derivatives: Fentanyl, Pethidine, Methadone,
Tramadol and Propoxyphene
Loperamide, an opiate that does not enter the brain and
therefore lacks analgesic activity.
Mechanism of Action
All opioid receptors are G-protein
coupled receptors and inhibit
They are also involved in
(increasing K+ efflux)
Reducing presynaptic Ca++ influx
thus inhibits neuronal activity.
All opioid receptors are linked through G-proteins to
inhibition of adenylate cyclase. They also facilitate
opening of potassium channels (causing
hyperpolarisation) and inhibit opening of calcium
channels (inhibiting transmitter release).
They are of 4 types:
μ-Receptors are thought to be responsible for most of the
analgesic effects of opioids, and for some major unwanted
effects. Most of the analgesic opioids are μ-receptor
κ-Receptors contribute to analgesia at the spinal level and
may elicit sedation and dysphoria, but produce relatively
few unwanted effects and do not contribute to
δ-Receptors are probably more important in the periphery
and may also contribute to analgesia.
σ-Receptors are not true opioid receptors and it is unclear
that what delta actually responsible for but may regulate
mu receptor activity.
Agonist and Antagonist
Opiates vary not only in their receptor specificity but also
in their efficacy at the different types of receptor. Thus
some agents act as agonists on one type of receptor, and
antagonists or partial agonists at another, producing a
very complicated pharmacological picture.
This group includes most of the typical morphine-like
drugs. They all have high affinity for μ receptors and
generally lower affinity for δ and κ sites. Some drugs of
this type, notably codeine, methadone are sometimes
referred to as weak agonists because their maximal
effects, both analgesic and unwanted, are less than those
of morphine, and they do not cause dependence.
Whether they are truly partial agonists is not established.
Pure agonist drugs include Morphine, Heroin, Methadone,
Morphine is the major analgesic drug contained in crude
opium and is the prototype strong agonist.
Morphine may be given by injection (intravenous or
intramuscular) or by mouth, often as slow-release tablets.
It is metabolized to morphine-6-glucuronide, which is
more potent as an analgesic.
Actions of Morphine:
Euphoria and sedation
Respiratory depression and suppression of cough
Nausea and vomiting
Reduced gastrointestinal motility, causing constipation
Histamine release, causing bronchoconstriction.
Drug of addiction due to euphoric effect
Over dose causes poisoning i.e. Coma and Respiratory
Cause dryness of mouth, mental clouding, vomiting,
headache, fatigue, constipation etc.
Methadone is a synthetic, orally effective opioid that is
approximately equal in potency to morphine but
induces less euphoria and has somewhat longer
duration of action.
Methadone is readily absorbed following oral
administration. The drug is biotransformed in the liver
and is excreted in the urine, mainly as inactive
Adverse effects: Methadone can produce physical
dependence like that of morphine.
Fentanyl and sufentanil are highly potent
phenylpiperidine derivatives, with actions similar to
those of morphine but with a more rapid onset and
shorter duration of action, particularly sufentanil. Their
main use is in anesthesia, and they may be given
intrathecally. They are also used in patient-controlled
infusion systems, where a short duration of action is
advantageous, and in severe chronic pain, when they are
administered via patches applied to the skin.
Partial Agonist and Mixed
These drugs, nalorphine and pentazocine, combine a degree
of agonist and antagonist activity on different receptors.
Nalorphine, for example, is an agonist when tested on
guinea pig ileum, but it also inhibits competitively the
effect of morphine on this tissue. Pentazocine and
cyclazocine, on the other hand, are antagonists at μ-
receptors but partial agonists on δ and κ-receptors. Most of
the drugs in this group tend to cause dysphoria rather than
euphoria, probably by acting on the κ-receptor.
Others include Buprenorphine, Nalbuphine, Pentazocine.
Nalorphine is closely related in structure to morphine and
has a more complicated action. In low doses, it is a
competitive antagonist and blocks most actions of
morphine in whole animals or isolated tissues. Higher
doses, however, are analgesic and mimic the effects of
morphine. These effects probably reflect an antagonist
action on μ-receptors, coupled with a partial agonist action
on δ and κ-receptors, the latter causing dysphoria, which
makes it unsuitable for use as an analgesic.
Pentazocine is a mixed agonist-antagonist with analgesic
properties similar to those of morphine. However, it
causes marked dysphoria, with nightmares and
hallucinations, rather than euphoria, and is now rarely
Buprenorphine is a partial agonist on μ receptors. It is
less liable to cause dysphoria than pentazocine but more
liable to cause respiratory depression.
These drugs produce very little effect when given on their
own but block the effects of opiates.
The most important examples are:
Naloxone was the first pure opioid antagonist, with affinity
for all three opioid receptors.
The main clinical uses of naloxone are to treat respiratory
depression caused by opiate over dosage. It is usually given
intravenously, and its effects are produced immediately. It
is rapidly metabolized by the liver, and its effect lasts only
2-4 hours, which is considerably shorter than that of most
morphine-like drugs. Therefore it may have to be given
Naloxone has no important unwanted effects of its own but
precipitates withdrawal symptoms in addicts. It can be used
to detect opiate addiction.
Naltrexone is very similar to naloxone but with the
advantage of a much longer duration of action (half-life
about 10 hours). It may be of value in addicts who have
been 'detoxified', because it nullifies the effect of a dose of
opiate should the patient's resolve fail. Its use in other
conditions, such as alcoholism and septic shock, is being
investigated, although the role of opioid peptides in these
conditions is controversial.
Specific antagonists at μ, δ and κ-receptors are available for
experimental use but not yet for clinical purposes.
Drugs Uses Adverse Effects
Morphine Widely used for acute
and chronic pain
Methadone Chronic pain
Maintenance of addicts
As morphine but
little euphoric effect
Accumulation may occur
because of long half-life
Pethidine Acute pain As morphine,
Risk of excitement and
Pentazocine Mainly acute pain Irritation at injection site.
Fentanyl Acute pain
Codeine Mild pain Mainly constipation
No dependence liability
Dextropropoxyphene Mild pain Respiratory depression
May cause convulsions
No longer recommended
Tramadol Acute (mainly
May cause convulsions
Non Narcotic Analgesics
Popular, safer alternate to Aspirin (as anti-pyretic and
Used in both adults and children
Over the counter drug (OTC)
Rapidly absorbed, mostly metabolized by conjugation
and excreted by kidney
Very less adverse effect in there therapeutic dose
Mechanism of Action
Paracetamol has no significant action on COX-1 and COX-2,
which left its mode of action a mystery but did explain its
lack of anti-inflammatory action and also, more
importantly, its freedom from gastrointestinal side effects
typical of NSAIDs.
Now, recent research has shown the presence of a new,
previously unknown cyclooxygenase enzyme COX-3,
found in the brain and spinal cord, which is selectively
inhibited by paracetamol, and is distinct from the two
already known cyclooxygenase enzymes COX-1 and
It is now believed that this selective inhibition of the enzyme
COX-3 in the brain and spinal cord explains the
effectiveness of paracetamol in relieving pain and reducing
fever without having unwanted gastrointestinal side
The action of paracetamol at a molecular level is unclear but
there is considerable evidence that the analgesic effect of
paracetamol is central and is due to activation of
descending serotonergic pathways, but its primary site of
action may still be inhibition of PG synthesis.
Useful in mild to moderate pain like headache, pyrexia,
In case of patients allergic to Aspirin
Patient with hemophilia.
Patient with PUD (peptic ulcer disease)
Patients who are taking other uricosuric drugs
(salicylate competes with the uric acid in tubular
Flupirtine is a centrally acting, non-opioid analgesic that is
available in a number of European countries for the
treatment of a variety of pain states.
Flupirtine acts indirectly as NMDA receptor antagonist by
activation of K+ channels. Activation of this channel leads to
hyperpolarization of neuronal membrane and the neuron
becomes less excitable; thus, there is stabilization of resting
neuronal membrane. Experimental evidence suggests that
flupirtine might suppress channel opening by acting as an
oxidizing agent at the redox site of the NMDA receptor.
This action inhibits the transmission of nociceptive impulses
during neuronal excitation.
Ziconotide (Prialt) is a non-narcotic pain reliever that is
used to treat severe chronic pain in people who cannot
use or do not respond to standard pain-relieving
Mechanism: Ziconotide acts as a selective N-type voltage-
gated calcium channel blocker. This action inhibits the
release of nociceptive neurochemicals
like glutamate and substance P in the brain and spinal
cord, resulting in pain relief.
In humans, spinal infusion of Prialt produces significant
pain relief in patients with intractable pain associated
with cancer, AIDS and in some neuropathic pain
Rang & Dales Pharmacology, 6th Edition.
Lippincott Pharmacology, 5th Edition.
Methling, K; Reszka P; Lalk M; Vrana O; Scheuch E; Siegmund
W; Terhaag B; Bednarski PJ (2008). "Investigation of the in Vitro
Metabolism of the Analgesic Flupirtine". 37: 479–493.
Klotz U (2009). "Ziconotide—a novel neuron-specific calcium
channel blocker for the intrathecal treatment of severe chronic
pain—a short review". Int J Clin Pharmacol Ther 44(10): 478–83.